EP1827583A1 - Implantable hermetically sealed structures - Google Patents
Implantable hermetically sealed structuresInfo
- Publication number
- EP1827583A1 EP1827583A1 EP05855386A EP05855386A EP1827583A1 EP 1827583 A1 EP1827583 A1 EP 1827583A1 EP 05855386 A EP05855386 A EP 05855386A EP 05855386 A EP05855386 A EP 05855386A EP 1827583 A1 EP1827583 A1 EP 1827583A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hermetically sealed
- implantable
- sealed structure
- structure according
- holder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/37512—Pacemakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37205—Microstimulators, e.g. implantable through a cannula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/3756—Casings with electrodes thereon, e.g. leadless stimulators
Definitions
- the inventive miniaturized, corrosion resistant hermetic package provides, for the first time, protection for an effector, e.g., that includes an integrated circuit (IC), in long term contact with saline, blood or other body fluid in a size form that is orders of magnitude smaller than previously available designs.
- This packaging has, by design, a uniquely miniaturized form factor.
- the present invention allows the practical development of miniaturized, implantable medical devices for days, months, and even years of practical, reliable use.
- aspects of the invention include implantable hermetically sealed structures dimensioned to be placed inside a lead, e.g., a cardiovascular lead, left ventricular lead, epicardial lead, etc.
- the structure comprises an effector, e.g., an actuator (such as an electrode) and/or a sensor.
- the effector includes an integrated circuit.
- Embodiments of the structures are configured to remain hermetically sealed in a saline environment for at least 10 years.
- Embodiments of the structures include an in vivo corrosion resistant holder having at least one conductive feedthrough; and a sealing layer; wherein the sealing layer and holder are configured to define a hermetically sealed volume.
- the conductive feedthrough may be a metal (e.g., platinum, iridium etc.), an alloy of metal and a semiconductor, a nitride, a semiconductor or some other convenient material.
- the corrosion resistant holder comprises silicon or a ceramic.
- the corrosion resistant holder comprises walls that are at least about 1 ⁇ m thick, such as at least about 50 ⁇ m thick, and ranges in certain embodiments from about 1 to about 125 ⁇ m, including from about 25 to about 100 ⁇ m, e.g., about 75 ⁇ m.
- the sealing layer is metallic, such as a noble metal, e.g., platinum or alloy thereof, containing sealing layer.
- the sealing layer is at least about 0.5 ⁇ m thick, such as at least about 2.0 ⁇ m thick, including at least about 20 ⁇ m thick and ranges in certain embodiments from about 0.5 to about 100 ⁇ m, such as from about 1 to about 50 ⁇ m, e.g., about 10 ⁇ m.
- the structure further includes an insulative material present in the hermetically sealed volume.
- the hermetically sealed volume ranges from about 1 pi to about 1 ml.
- the structure is electrically coupled to at least one elongated conductive member, where the elongated conductive member may be electrically coupled to a control unit, such as one that is present in a pacemaker can.
- aspects of the invention further include methods of making a hermetically sealed structure, where the methods include: positioning an effector through an opening in an in vivo corrosion resistant holder; and fabricating a sealing layer over the opening to seal the effector in the holder in a hermetically sealed volume; wherein said method further comprises producing a conductive feedthrough in said holder that is electrically coupled to said effector, e.g., by filling a passage in said holder with a conductive material and further melting a solder material positioned between said effector and said conductive feedthrough or filling a passage in the holder with a conductive material and contacting the effector in a single process step.
- the methods further include planarizing said holder prior to producing said sealing layer.
- the holder is present in a structure that includes multiple chip holders and said the further includes separating the multiple chip holders to produce the hermetically sealed structure.
- aspects of the invention further include implantable medical devices that include a hermetically sealed structure of the invention.
- the structure is present in a lead, such as a cardiovascular lead, a left ventricular lead or an epicardial lead.
- the device is chosen from a neurological device, a muscular device, a gastrointestinal device, a skeletal device, a pulmonary device, an opthalmic device and an auditory device.
- the device includes two or more of the hermetically sealed structures.
- aspects of the invention further include methods of implanting an implantable medical device of the invention into a subject; and using said effector of said implanted medical device.
- systems and kits that include a hermetically sealed structure according to the invention; and a control unit.
- FIG. 1 provides a three-dimensional representation of an in vivo corrosion resistant holder according to an embodiment of the invention.
- FIGS. 2A and 2B show different three-dimensional views of a hermetically sealed integrated circuit according to an embodiment of the invention.
- FIGS. 3A and 3B show different cross-sectional views of assemblies with multiple hermetically sealed integrated circuits according to alternative embodiments of the invention.
- FIGS. 4A to 4M are diagrams showing a method for fabricating a hermetically sealed structure according to an embodiment of the invention.
- FIGS. 5A to 5L are diagrams showing a method for fabricating a hermetically sealed structure according to an embodiment of the invention.
- FIGS. 6A to 6H are diagrams showing a method for fabricating a hermetically sealed structure according to an embodiment of the invention.
- FIG. 7 provides a depiction of a cardiac resynchronization therapy system that includes one or more hermetically sealed integrated circuits coupled to lead electrodes according to an embodiment of the invention.
- FIG. 8 provides a depiction of a lead electrode coupled to a hermetically sealed integrated circuit according to an embodiment of the invention.
- aspects of the invention provide implantable hermetically sealed structures and methods for making and using the same. Also provided are devices, systems and kits including the hermetically sealed structures, as well as methods of using such devices and systems.
- hermetically sealed structures are reviewed first in greater detail. Next, embodiments of production protocols for manufacturing the hermetically sealed structures are reviewed. Embodiments of devices and devices, such as implantable medical devices and systems, that include hermetically sealed structures of the invention are then described, as well as methods of using such devices in different applications. Also provided is a description of kits that incorporate aspects of the invention.
- embodiments of the invention include implantable hermetically sealed structures.
- the structure can functionally survive (i.e., without substantial, if any, compromise of the function) for a substantial period in a saline environment, such as in a physiological environment in which they are in contact with blood, and/or tissue.
- the structures do not deteriorate in terms of function, e.g., as determined by function of an effector sealed inside of the structure, for a period of at least about 2 or more days, such as at least about 1 week, at least about 4 weeks, at least about 6 months, at least about 1 year or longer, e.g., at least about 5 years or longer.
- the hermetically sealed structures provide hermetic protection to effectors present therein when implanted at a physiological site for a period ranging from about 1 to about 80 years or longer, such as from about 5 to about 70 years or longer, and including for a period ranging from about 10 to about 50 years or longer. Furthermore, the integrity of the hermetic seal is maintained despite the implanted structure being subjected to significant voltage variations, e.g., ranging from about 0.1V to about 100 V, such as from about 1V to about 5V. Because the hermetically sealed structures are able to survive in high humidity, salt spray environments, they have many important applications outside use in the human body, e.g., in other high reliability assemblies that would be subject to salt water and/or high humidity. However, for ease of description only, aspects of the hermetically sealed structures are further described herein primarily in terms of implantable medical device embodiments.
- the hermetically sealed structures are dimensioned to be placed inside a cardiovascular lead.
- dimensioned to be placed inside of a cardiovascular lead is meant that the hermetically sealed structures have a sufficiently small size (i.e., form factor) such that they can be positioned inside of a cardiovascular lead.
- the hermetically sealed structures have a longest dimension, e.g., length, width or height, ranging from about 0.05 mm to about 20 mm, such as from about 0.2 mm to about 5 mm, including from about 0.5 mm to about 2 mm.
- embodiments of the structures have a size that is orders of magnitude smaller than previously available designs. Accordingly, embodiments of the structures allow the practical development of miniaturized, implantable medical devices for days, months, and even years of practical, reliable use.
- the hermetically sealed structure includes a hermetically sealed volume that houses one or more effectors.
- effector is generally used herein to refer to sensors, activators, sensor/activators, actuators (e.g., electromechanical or electrical actuators) or any other device that may be used to perform a desired function.
- effectors include a transducer and a processor (e.g., in the form of an integrated circuit (digital or analog).
- embodiments of the invention include ones where the effector comprises an integrated circuit.
- integrated circuit is used herein to refer to a tiny complex of electronic components and their connections that is produced in or on a small slice of material, i.e., chip, such as a silicon chip.
- the IC is an IC as described in PCT Patent Application Serial No. PCT/US2005/ titled
- the effectors may be intended for collecting data, such as but not limited to pressure data, volume data, dimension data, temperature data, oxygen or carbon dioxide concentration data, hematocrit data, electrical conductivity data, electrical potential data, pH data, chemical data, blood flow rate data, thermal conductivity data, optical property data, cross-sectional area data, viscosity data, radiation data and the like.
- the effectors may be sensors, e.g., temperature sensors, accelerometers, ultrasound transmitters or receivers, voltage sensors, potential sensors, current sensors, etc.
- the effectors may be intended for actuation or intervention, such as providing an electrical current or voltage, setting an electrical potential, heating a substance or area, inducing a pressure change, releasing or capturing a material or substance, emitting light, emitting sonic or ultrasound energy, emitting radiation and the like.
- Doppler Doppler, pressure sensors, additional wall motion, and other cardiac parameter sensing devices, which effector devices or at least components thereof can be hermetically sealed according to embodiments of the invention, as desired.
- Some of these are embodied in currently filed provisional applications; "One Wire Medical Monitoring and Treating Devices", U.S. Provisional Patent Application No. 60/607280 filed
- hermetically sealed structures that include: an in vivo corrosion resistant holder having at least one conductive feedthrough; and a sealing layer; where the sealing layer and the holder are configured to define a hermetically sealed volume, e.g., in which one or more effectors is present. Selection of appropriate dimensions and/or materials for these elements, as reviewed in greater detail below, provides for the implantable functionality of the hermetically sealed structures, e.g., as reviewed above.
- the in vivo corrosion resistant holder is a structure that is configured to hold an effector(s), e.g., such that the effector is bounded on all but one side by the walls of the holder.
- the holder includes side walls and a bottom.
- the holder may have a variety of different configurations so long as it is able to contain the effector of interest in a manner such that the effector is held in a volume bounded on all but one side. Accordingly, the shape of the holder may be square, circular, ovoid, rectangular, or some other shape as desired.
- the holder may be fabricated from a variety of different materials, including, but not limited to: silicon (e.g., single crystal, polycrystalline, etc), ceramics, e.g., silicon carbide, alumina, aluminum oxide, aluminum nitride, boron nitride, beryllium oxide, among others; diamond-like carbon, sintered materials, etc.
- the holder is fabricated from a material that is transparent to light, at least in a certain wavelength range, e.g., infrared light. Virtually any ceramic can be employed for the holder as long as the ceramic selected meets the corrosion requirements of a particular assembly and its intended environment. When multiple materials are employed, the coefficients of thermal expansion may be taken into account in the material selection so that the materials do not negatively impact the functionality of an effector sealed in the structure.
- the holders include one on or more conductive feedthroughs positioned in a wall or bottom of the holder.
- the conductive feedthrough is, in certain embodiments, a relatively thick conductive material present in the bottom of the holder.
- relatively thick is meant that it has a thickness ranging from about 0.001 mm to about 1 mm, such as from about 0.01 mm to about 0.1 mm. In certain embodiments, the thickness ranges from about 12 to about 375 ⁇ m, such as from about 20 to about 125 ⁇ m, e.g., 75 ⁇ m.
- the conductive feedthrough may be fabricated from a variety of different materials.
- Suitable materials of interest include, but are not limited to: metals, e.g., noble metals and alloys thereof, such as gold (Au), silver (Ag), nickel (Ni), Osmium (Os), palladium (Pd), platinum (Pt), rhodium (Rh), and iridium (Ir), where in certain embodiments the noble metal is not gold or an alloy thereof.
- the conductive material is a gold alloy.
- Metals that may be combined with a noble metal in the production of suitable noble metal alloys include, but are not limited to other noble metals, titanium (Ti), chromium (Cr), tungsten (W), and the like.
- conductive materials are alloys of noble metals with semiconductor materials, e.g., metal suicides, as reviewed in greater detail below.
- an in vivo corrosion resistant holder has structure as depicted three-dimensionally in FIG. 1.
- in vivo corrosion resistant holder 10 is a rectangular container that includes four walls, 12, 14, 16 and 18, and bottom 20. As such, the walls and bottom of the holder define a contained volume that is bounded on all but one side with material.
- the width of the walls and thickness of the bottom may vary and, in certain embodiments, is selected to be sufficient to provide for the desired corrosion resistance for the time the structure is to be present in the in vivo environment.
- the width of the walls and thickness of the bottom range from about 0.001 mm to about 10 mm, such as from about 0.01 mm to about 1.0 mm, including from about 0.025 mm to about 0.25 mm.
- the volume contained on all but one side in the structure shown in FIG. 1 may vary, e.g., depending on whether a single or multiple effectors are to be sealed in the structure, and in certain embodiments ranges from about 1 pi to about 1 ml, such as from about 1 ⁇ l to about 100 ⁇ l, including from about 0.1 ⁇ l to about 1 ⁇ l.
- conductive feedthroughs 22, 24, 26 and 28, which provide for conductive connection from the inner bottom surface of the holder to external connector elements 32, 34, 36 and 38. While the holder is depicted as having four different conductive feedthroughs, any desired number of feedthroughs may be present, e.g., 1 or more, as reviewed above, such as from about 1 to about 1000, e.g., from about 2 to about 100, including from about 3 to about 10. Furthermore, the conductive feedthroughs may be fabricated from any convenient material, e.g., noble metal such as platinum or alloy thereof, suicide such as metal suicide (as reviewed in greater detail below), etc.
- the holder can be fabricated using a number of different protocols, including planar processing protocols in which structures are built up and/or removed from a surface or surfaces of an initially planar substrate using a variety of different material removal and deposition protocols applied to the substrate in a sequential manner.
- the open end of the holder is sealed with a sealing layer.
- the sealing layer is a layer that is of sufficient thickness fabricated from a suitable material to define a hermetically sealed volume bounded on one side, e.g., top, by the sealing layer and on every other side by the internal walls of the holder.
- the sealing layer is at least about 0.1 ⁇ m or thicker, and in certain embodiments ranges from about 0.01 to about 100 ⁇ m, such as from about 0.1 to about 50 ⁇ m, including from about 1 to about 10 ⁇ m.
- the sealing layer may be fabricated, a number of different materials may be used including, but not limited to metals, e.g., noble metals and alloys thereof, such as described above, e.g., platinum, rhodium, iridium, and alloys thereof, metal suicides (e.g., as reviewed below), nitrides, e.g., aluminum nitrides, silicon nitrides, titanium nitride, carbides, etc.
- the sealing layer i.e., top cap metallization
- the sealing layer is a dielectric, e.g., aluminum nitride, tungsten carbide, silicon carbide, etc.
- a design is employed that mitigates the differences of coefficients of thermal expansion between the thick platinum metallization and the ceramic or silicon holder is provided.
- the platinum is interlaced with an array of etched silicon or ceramic ribs in between. This design minimizes the total volume of material that is experiencing expansion and or contraction.
- the outside metallization can be platinum, or any noble metal, by example iridium, rhodium, or osmium, or alloys thereof.
- An adhesion promoting layer may be included between the sealing layer and the holder which enhances adhesion of the sealing layer and holder.
- This adhesion promoting layer may vary, where suitable layers include, but are not limited to: titanium/tungsten, " chromium, platinum oxide, and the like. Also of interest are suicides, e.g., as reviewed in greater detail below.
- the sealing layer can be adhered to the structure using a number of different protocols, including, but not limited to: diffusion bonding, welding, soldering, brazing, compression bonding, ultrasonic bonding, thermosonic bonding, thermocompression bonding, anodic bonding, etc.
- the sealing layer is, in turn, coated with a dielectric, e.g., silicon carbide, silicon oxide, silicon nitride, etc.
- a dielectric e.g., silicon carbide, silicon oxide, silicon nitride, etc.
- the entire assembly can optionally be coated with a plastic, as desired.
- FIG. 2A provides a three-dimensional view of a hermetically sealed structure according to an embodiment of the invention.
- structure 200 includes holder 210 and sealing layer 220. Sealing layer 220 and holder 210 are configured to define a hermetically sealed volume (not shown) inside the holder. Also shown are external connector elements 212, 213, 214, 215, 216 and 217, which are coupled to conductive feedthroughs (not shown) present in the bottom of the holder.
- FIG. 2B provides a three-dimensional cut-away view of a hermetically sealed structure according to an embodiment of the invention.
- holder 210 and sealing layer 220 define a hermetically sealed volume 250 what holds an effector (e.g., comprising an integrated circuit) 230.
- the effector 230 is electrically coupled to the conductive (e.g., platinum) feedthroughs or vias 212 with a solder alloy (e.g., lead tin, gold tin, silver tin, or other suitable alloys) 240.
- a solder alloy e.g., lead tin, gold tin, silver tin, or other suitable alloys
- any space between an effector and the walls of the holder and/or sealing layer may be occupied by an insulating material.
- Any convenient insulating material may be employed, where representative insulating materials include, but are not limited to: liquids, e.g., silicon oil, elastomers, thermoset resins, thermoset plastics, epoxies, silicones, liquid crystal polymers, polyamides, polyimides, benzo-cyclo-butene, ceramic pastes, etc.
- FIG. 3A provides a cross-sectional view of a hermetically sealed structure according to an embodiment of the invention.
- the holder 300 includes two distinct wells 311 and 312, positioned side by side, e.g., in an array format, where each well houses two different effectors 313 and 314 (e.g., integrated circuits).
- Each well includes sides 315 and a bottom 316.
- conductive feedthroughs 317, 318, 319 and 320 are also shown in the bottom of each well. Electrically coupling the traces 331, 332, 333 and 334 of integrated circuits 313 and 314 to the conductive feedthroughs. Electrically coupling the traces 331, 332, 333 and 334 of integrated circuits 313 and 314 to the conductive feedthroughs.
- solder connections 321, 322, 323 and 324 Separating the different solder connections from each other is insulating material 340.
- a suitable insulating material may also be present in the spaces between the effectors and the sides/bottom of the wells of the holder.
- a sealing layer is present on the surface opposite the feedthroughs, although not shown in FIG. 3A. While the depiction of FIG. 3A shows only two different integrated circuits hermetically sealed, structures of the invention may include many more integrated circuits, e.g., 4, 5, 6, or more circuits, in any convenient arrangement.
- One embodiment of the multiple chips per package design is to have a chip that is fabricated or otherwise designed to withstand higher voltages in one section of the assembly.
- the companion chip has a lower voltage tolerance than the first chip, but would not need the capacity of sustaining high voltages from cardiac pacing or other component demands from another part of the assembly. Both of those chips are dropped into the same hermetic packaging, e.g., in the same well or side by side wells, attached with a soldering process and then secured in place with an insulating material (i.e., potted), planarized or lapped back, e.g., as reviewed below, and then covered with a sealing layer.
- an insulating material i.e., potted
- structure 350 includes holder 360 with sides 362 and bottom 364 defining well 366.
- well 366 Present in well 366 are two different effectors 371 and 372 stacked on top of each other.
- insulating material 370 Separating the different solders from each other is insulating material 370.
- a suitable insulating material may also be present in the spaces between the effectors and the sides/bottom of the well of the holder.
- a sealing layer is present on the surface opposite the feedthroughs, although not shown in FIG. 3B.
- Embodiments of the hermetically sealed structures may be fabricated using any convenient protocol. Aspects of these embodiments of the invention include placing one or more effectors in an in vivo corrosion resistant holder; and producing a sealing layer over the opening of the holder to seal the one or more effectors in the holder in a hermetically sealed volume. Depending on the nature of the effector, embodiments of the methods further include electrically coupling the effector to a conductive feedthrough present in the holder. Furthermore embodiments of the methods include making the corrosion resistant holders.
- any of a variety of different protocols may be employed in manufacturing the sealed structures and components thereof.
- molding, deposition and material removal e.g., planar processing techniques, such as Micro-Electro- Mechanical Systems (MEMS) fabrication, may be employed.
- Deposition techniques that may be employed in certain aspects of fabrication the structures include, but are not limited to: electroplating, cathodic arc deposition, plasma spray, sputtering, e-beam evaporation, physical vapor deposition, chemical vapor deposition, plasma enhanced chemical vapor deposition, etc.
- lithographic protocols Of interest in certain embodiments is the use of planar processing protocols, in which structures are built up and/or removed from a surface or surfaces of an initially planar substrate using a variety of different material removal and deposition protocols applied to the substrate in a sequential manner. In a fabrication protocol according to an embodiment of the invention, the holder is first produced.
- the holder can be fabricated from any of a variety of different materials, including but not limited to: silicon (single or polycrystalline), silicon carbide (single or polycrystalline), alumina, or other appropriate ceramics.
- the holder may be produced by a number of different protocols, including molding, as well as material removal/deposition protocols employed in the manufacture of MEMS devices, where certain protocols are further illustrated below.
- holes e.g., in the form of trenches
- a conductive material to produce the conductive feedthroughs.
- EDM electronic discharge machining
- reactive ion etching grinding
- chemical etching chemical etching
- the holes are filled with a conductive material, e.g., metal, metal suicide, etc., to produce conductive feedthroughs.
- a conductive material e.g., metal, metal suicide, etc.
- the holes may be filled with the conductive material before or after the integrated circuit is positioned in the holder, depending on the particular protocol that is employed in fabrication of the structure.
- a base layer of a metal e.g., platinum, is applied, such as through a sputtering process if this assembly is going to be built up through electroplating.
- the trenches are then filled in using an electroplating, plasma enhanced chemical vapor deposition process, or through other appropriate means.
- the integrated circuit is placed in the holder first, followed by filling in of the holes with a conductive material, e.g., a metal.
- the integrated circuit may be positioned in the holder using any convenient protocol.
- the trace side of the integrated circuit die is positioned facing the bottom of holder so that electrical contact can be made between the traces of the circuit and the feedthrough(s) in the bottom of the holder.
- the integrated circuit may be covered with a thin film of one or more material, e.g., with a Pt thin film and then a silicon carbide film.
- the wafer may be positioned trace side up in the holder and electrical connection made to the conductive feedthroughs of the holder by the through wafer vias.
- aspects of the methods include establishing an electrical connection between the circuitry of the integrated circuit and the conductive feedthroughs.
- electrical connection is established by providing a suitable solder material, e.g., gold, gold tin, or silver tin solder, present (e.g., bumped) on the surface.
- the resulting assembly is heated to above the melting point of the solder to form electrical contact with the feedthroughs in the holder.
- a suitable insulative material e.g., polyimide, an epoxy or a low melting point glass, where the material is generally one that is compatible with the deposition process of the sealing layer, e.g., metal sealing layer, that follows.
- this step of the protocol of these embodiments includes producing a sealing layer across the surface of the structure opposite the bottom of the surface, which surface is defined by the tops of the walls of the holder, the bottom (non-circuit side) of the integrated circuit and any insulative material.
- the surface of the structure may be planarized, (i.e., lapped) to produce a uniform surface substantially free of any irregularities, e.g., bumps, cracks, etc.
- the uniform height of the resultant lapped surface allows the formation of a crack free protective layer. This step ensures that no irregularities are present on the surface that may adversely impact the structural integrity of the sealing layer that is produced on the top surface.
- the surface, (i.e., top) of the resulting structure is then covered with a sealing layer, e.g. a sputtered Pt film.
- additional material may be plated onto the initial layer for enhanced thickness, e.g., where the sputtered film is then covered with Pt plating.
- the IC chip is covered with a Pt thin film and then a silicon carbide film.
- any of the top, bottom or side surfaces of the structure may be further coated with an additional material, e.g., a dielectric such as silicon carbide, silicon oxide, silicon nitride, aluminum nitride, tungsten carbide, etc.
- both metal and dielectric layers may be present, stacked in any of variety of different sequences, as desired.
- FIGS. 4A to 4M provide a flow diagram of a processing protocol according to an embodiment of the invention that can be employed to manufacture a hermetically sealed structure, which process may be referred to as a "shadow mask" process.
- initial structure 400 includes base layer 405 (e.g., silicon, silicon carbide, etc.) which has mask layer 410 present on a first surface 408.
- base layer 405 e.g., silicon, silicon carbide, etc.
- mask layer 410 present on a first surface 408.
- shallow recesses 404 e.g., in the form of trenches
- These recesses will ultimately become the conductive feedthroughs, as shown below.
- structure 400 includes recesses 404 present on surface 408, as shown in FIG. 4C.
- a shadow mask 412 is placed on the surface 408 of base layer 405 as shown in FIG. 4D.
- Shadow mask 412 may be produced using any convenient protocol, e.g., by reactive ion etching, photoetching or electroforming, etc.
- a conductive layer 417 e.g., of a metal, is then produced across the upper surface 408 and mask 412 of structure 400, as shown in FIG. 4E, e.g., via deposition, plating, etc.
- the conductive layer 417 completely fills recesses 404 on surface 408.
- the mask layer 412 is planarized, as shown in FIG.
- structure 400 may be considered a microfabricated chip package that includes: an array of feedthroughs fabricated, e.g., using planar processing techniques, and an array of cavities, e.g., fabricated using planar processing techniques. This step results in the production of holders 430 having side walls 431 and bottoms 432, where the bottoms 432 include conductive elements 420 which are now conductive feedthroughs, e.g., of a metal or a doped semiconductor material.
- FIG. 4I shows placement of integrated circuits 440 into holders 430, where the integrated circuit traces 441 are electrically isolated from each other by insulative material 443. Also shown are solders 442 which provide for electrical connection between traces 441 and conductive elements (i.e., feedthroughs) 420.
- insulative material 450 e.g., epoxy
- FIG. 4K surface 422 has been planarized (i.e., lapped) to produce new planar surface 460 that is free of surface irregularities.
- FIG. 4L shows the production of sealing layer 470 on planar surface 460.
- a structure in this figure, includes an array of holders each with integrated feedthroughs, where each chip holder contains an integrated circuit, an insulative material fills the space between the integrated circuit and the walls of the holders.
- the structure is further characterized in that the insulative material, integrated circuits and array of chip holders has been planarized and a corrosion resistant material that covers the planarized array of chip holders is present.
- structure 400 has been cleaved to produce hermetically sealed integrated circuits 481 and 482, as shown in FIG. 4M.
- FIGS. 5A to 5L provide a flow diagram of a processing protocol according to an embodiment of the invention that can be employed to manufacture a hermetically sealed structure, which process may be referred to as a "damascene" process.
- initial structure 500 includes base layer 505 (e.g., silicon, silicon carbide, etc.) which has mask layer 510 present on a first surface 508.
- base layer 505 e.g., silicon, silicon carbide, etc.
- mask layer 510 present on a first surface 508.
- shallow recesses 504 e.g., in the form of trenches
- structure 500 includes recesses 504 present on surface 508, as shown in FIG. 5C.
- a conductive layer 517 e.g., of a metal
- FIG. 5D e.g., via deposition, plating, etc.
- the conductive layer 517 completely fills recesses 504 on surface 508.
- the top surface 515 is planarized, e.g., by lapping or chemical-mechanical polishing, etc., as shown in FIG. 5E, leaving conductive elements 520 present on surface 515 of base 505, such that surface 515 is planar.
- mask layer 525 is produced on bottom surface 522.
- FIG. 5G shows material is removed from bottom surface 522 as shown in FIG. 5G.
- This step results in the production of holders 530 having side walls 531 and bottoms 532, where the bottoms 532 include conductive elements 520 which are now conductive feedthroughs.
- FIG. 5H shows placement of integrated circuits 540 into holders 530, where the integrated circuit traces 541 are insulated from each other by insulative material 543. Also shown are solders 542 which provide for electrical connection between traces 541 and conductive elements (i.e., feedthroughs) 520.
- mask layer 525 has been removed from bottom surface 522.
- insulative material 550 e.g., epoxy, is introduced into holders 530 to fill any gaps between the integrated circuit and holder walls/bottom, as shown in FIG.
- FIG. 5I shows the production of sealing layer 570 on planar surface 560.
- structure 500 has been cleaved to produce product hermetically sealed integrated circuits 581 and 582, as shown in FIG. 5L.
- FIGS. 6A to 6L provide a flow diagram of a processing protocol according to an embodiment of the invention that can be employed to manufacture a hermetically sealed structure, which process may be referred to as a "solder-free" process.
- FIG. 6A to 6L provide a flow diagram of a processing protocol according to an embodiment of the invention that can be employed to manufacture a hermetically sealed structure, which process may be referred to as a "solder-free" process.
- initial structure 600 includes base layer 605 (e.g., silicon, silicon carbide, etc.) which has mask layer 610 present on a first surface 608. Following removal, e.g., via plasma etching techniques, shallow recesses 604 (e.g., in the form of trenches) are produced on first surface 608 as shown in FIG. 6B. These recesses will ultimately become the conductive feedthroughs, as shown below. Following removal of mask layer 610, structure 600 includes recesses 604 present on surface 608, as shown in FIG. 6C. In addition, a mask layer 625 is produced on bottom surface 622. Next, material is removed from bottom surface 622 as shown in FIG. 6D.
- base layer 605 e.g., silicon, silicon carbide, etc.
- FIG. 6E shows placement of integrated circuit 640 into holders 630, where the integrated circuit traces 641 are insulated from each other by insulative material 643.
- mask layer 625 has been removed from bottom surface 622.
- a second mask layer 612 is placed on the surface 608 of base layer 605 as shown in FIG. 6F.
- a conductive layer 617 e.g., of a metal, is then produced across the upper surface 608, as shown in FIG. 6G, e.g., via deposition, plating, etc.
- the conductive layer 617 completely fills recesses 604 on surface 608.
- top surface 615 is planarized, as shown in FIG. 6H, leaving conductive feedthroughs 620 present on surface 618 of base 605, such that conductive feedthroughs 620 are in electrical communication with traces 641.
- the resultant structure is then processed further, e.g., as described above in connection with FIGS. 4A to 4M and FIGS. 5A to 5L. It is noted that the above described methods of fabrication are merely illustrative of different protocols that can be employed to manufacture the hermetically sealed structures according to the invention.
- SiLiciDE EMBODIMENTS As described above, certain embodiments include the use of alloys of metals and semiconductor materials, particularly metal suicides, in various components of the subject hermetically sealed structures.
- the metal and silicon containing material interdiffuse at the metal-Si interface to form a variety of new compounds depending upon the annealing temperature, annealing environment and annealing time.
- ruthenium, osmium, iridium, palladium and platinum suicides are typically of thicknesses in the range of from about 0.1 ⁇ m to about 0.5 ⁇ m but can range from about 0.01 ⁇ m to about 250 ⁇ m and are formed in certain embodiments between about 25 0 C and about 1500 0 C.
- the formation of a suicide alters the material structure and, as such, its chemical and mechanical properties.
- metal suicides provide increased corrosion resistance and increased substrate adhesion for both thin-film and bulk materials that make up the structures.
- a metal that has been converted into a suicide has increased corrosion resistance due to the material modification of its exposed surfaces for two reasons. First, though they remain electrically conductive, suicides form a protecting silicon dioxide layer at the surface. Secondly, the new material has very different electro-catalytic behavior than the base metal it was created from. The combination of the oxide layer and altered electro-catalytic behavior increases the impedance between the suicide and the solution. This increase in impedance reduces the current that is passed to the solution for a given applied voltage. Through Faraday's Law, this reduction in current is directly linked to the reduction of corrosion rate of the suicide.
- suicides can be both formed by annealing a thin metal film on a silicon substrate and a thin silicon film on metal substrate.
- the metal or silicon material can be completely or partially converted to a suicide.
- the stoichiometry of the resulting suicide can be tailored for a specific annealing temperature. This tailoring allows for the altering of material and electrical characteristics of the suicide and is another embodiment of the invention. If the annealing time is controlled, only the material immediately at the Si-metal interface may be turned to suicide.
- Suicides can be formed at temperatures as low as 25 0 C. As such, suicide processing steps are compatible with commercial CMOS circuits.
- suicide conductors can be patterned using a one-mask diffusion barrier.
- any un-silicided metal can be removed post anneal with an etchant that is selective to the metal relative to the suicide. The same is true for any unsilicided silicon on a metal substrate.
- a conductive suicide layer's relative thinness (0.1 ⁇ m to 1 ⁇ m) makes it easy to deposit additional dielectric and metal diffusion barriers on top of the suicide to improve corrosion resistance further such as silicon carbide, silicon nitride, alumina, polyimide and other polymers, and further metal layers such as platinum or iridium.
- the additional layering of thin films on top of the patterned suicide conductors represents another embodiment of the invention.
- a metal seal ring can be patterned on a silicon chip or wafer and this ring, when formed into a suicide, can be used to bond the chip to either another silicon chip or wafer or bulk metal sheet. Either embodiment creates a sealed cavity that is protected by either bulk material or corrosion-resistant suicide. This process can be performed at the die or wafer level.
- This inventive packaging scheme represents a substantial improvement over prior packaging methods that depend on a polymer or an easily corroded material for proper sealing.
- the coefficient of thermal expansion of a suicide may also be between that of the silicon and the metal. This reduces the thermal stress concentrations at the various material interfaces.
- Using a suicide material to attach a metal to silicon eliminates the need to use a dissimilar metal as an adhesion layer (i.e. Ti, TiW, Cr, or Au). This is attractive because these materials exhibit either poor corrosion behavior or bio-toxicity and should not be used within the human body.
- the improved adhesion is not limited to thin film applications.
- bulk metal preforms in the range of thicknesses from about 25 ⁇ m to about 1000 ⁇ m thick, such as from about 50 ⁇ m to about 500 ⁇ m thick can be inserted into recesses in silicon trenches or vias and annealed. The resulting thick suicide will be conductive, corrosion resistant and will provide sufficient thickness for the laser welding or soldering of electrical conductors.
- silicon preforms can be used with bulk metal substrates.
- Suicides undergo a volumetric expansion during formation. This fact can be used to ensure that that large trenches or through-hole vias in silicon are completely filled with suicide.
- Solid metal inserts can be positioned in silicon trenches via placement, formation or deposition and fully or partially suicided to form a strong bond with the surrounding silicon. The expansion and subsequent bond with the silicon wall of the suicide will eliminate any micro-gaps that may have been left unsealed during the positioning of the metal insert.
- aspects of the invention include devices and systems, including implantable medical devices and systems, that include the hermetically sealed structures according to embodiments of the invention.
- the devices and systems may perform a number of different functions, including but not limited to physiological parameter monitoring, pharmaceutical agent delivery, electrical stimulation, e.g., for medical purposes, analyte, e.g., glucose detection, etc.
- the implantable medical devices and system may have a number of different components or elements, where such elements may include, but are not limited to: sensors (e.g., cardiac wall movement sensors, such as wall movement timing sensors), cardiac stimulation elements and related structures, e.g., pacing leads with electrodes disposed thereon; processing elements, e.g., for controlling timing of cardiac stimulation, e.g., in response to a signal from one or more sensors; telemetric transmitters, e.g., for telemetrically exchanging information between the implantable medical device and a location outside the body; drug delivery elements, etc.
- sensors e.g., cardiac wall movement sensors, such as wall movement timing sensors
- cardiac stimulation elements and related structures e.g., pacing leads with electrodes disposed thereon
- processing elements e.g., for controlling timing of cardiac stimulation, e.g., in response to a signal from one or more sensors
- telemetric transmitters e.g., for telemetrically exchanging information between the implantable medical device
- the subject hermetically sealed structures may be operably coupled, e.g., in electrical communication with, components of a number of different types of implantable medical devices and system, where such devices and systems include, but are not limited to: physiological parameter sensing devices; drug delivery devices, electrical (e.g., cardiac) stimulation devices, etc.
- one or more hermetically sealed structures of the invention are electrically coupled via the conductive feedthrough to at least one elongated conductive member, e.g., an elongated conductive member present in a lead, such as a cardiovascular lead.
- the elongated conductive member is part of a multiplex catheter, e.g., as described in Published PCT Application No. WO 2004/052182 and US Patent Application No.10/734,490, the disclosure of which is herein incorporated by reference.
- the devices and systems may include onboard logic circuitry or a processor, e.g., present in a central control unit, such as a pacemaker can. In these embodiments, the central control unit may be electrically coupled to one or more hermetically sealed structures via one or more conductive members.
- the subject hermetically sealed structures find use in any medical device and system in which it is desired to implant for an extended period of time a hermetically sealed structure.
- Devices and systems in which the subject hermetically sealed structures find use include, but are not limited to, those described in: WO 2004/066817 titled “Methods And Systems For Measuring Cardiac Parameters”; WO 2004/066814 titled “Method And System For Remote Hemodynamic Monitoring”; WO 2005/058133 titled “Implantable Pressure Sensors”; WO 2004/052182 titled “Monitoring And Treating Hemodynamic Parameters”; WO 2004/067081 titled “Methods And Apparatus For Enhancing Cardiac Pacing”; U.S.
- PRO-P37 titled “Methods and Apparatus for Tissue Activation and Monitoring” filed 8/12/05; U.S. Provisional Patent Application No. 60/707,913 titled “Measuring Conduction Velocity Using One or More Satellite Devices,” filed 8/12/05. These applications are herein incorporated into the present application by reference in their entirety.
- cardiovascular function monitoring/pacing devices cardiovascular function monitoring/pacing devices
- blood analyte detection devices and systems blood analyte detection devices and systems
- vision restoration devices and systems are two illustrative types of devices and systems.
- the implantable medical devices and systems which include the subject hermetically sealed structures are ones that are employed for cardiovascular applications, e.g., pacing applications, cardiac resynchronization therapy applications, etc.
- FIG. 7 provides a cross-sectional view of the heart with of an embodiment of a cardiac resynchronization therapy (CRT) system that includes hermetically sealed integrated circuits according to embodiments of the invention.
- the system includes a pacemaker can 106, a right ventricle electrode lead 109, a right atrium electrode lead 108, and a left ventricle cardiac vein lead 107. Also shown are the right ventricle lateral wall 102, interventricular septal wall 103, apex of the heart 105, and a cardiac vein on the left ventricle lateral wall 104.
- the left ventricle electrode lead 107 is comprised of a lead body and one or more electrodes 110,111 , and 112. Each of the electrodes includes a hermetically sealed integrated circuit, as shown in FIG. 8 below. Having multiple distal electrodes allows a choice of optimal electrode location for CRT.
- electrode lead 107 is constructed with the standard materials for a cardiac lead such as silicone or polyurethane for the lead body, and MP35N for the coiled or stranded conductors connected to Pt-Ir (90% platinum, 10% iridium) electrodes 110,111 and 112.
- these device components can be connected by a multiplex system (e.g., as described in published United States Patent Application publication nos.: 20040254483 titled “Methods and systems for measuring cardiac parameters”; 20040220637 titled “Method and apparatus for enhancing cardiac pacing”; 20040215049 titled “Method and system for remote hemodynamic monitoring”; and 20040193021 titled “Method and system for monitoring and treating hemodynamic parameters; the disclosures of which are herein incorporated by reference), to the proximal end of electrode lead 107.
- the proximal end of electrode lead 107 connects to a pacemaker 106.
- the electrode lead 107 is placed in the heart using standard cardiac lead placement devices which include introducers, guide catheters, guidewires, and/or stylets. Briefly, an introducer is placed into the clavicle vein. A guide catheter is placed through the introducer and used to locate the coronary sinus in the right atrium. A guidewire is then used to locate a left ventricle cardiac vein. The electrode lead 107 is slid over the guidewire into the left ventricle cardiac vein 104 and tested until an optimal location for CRT is found. Once implanted a multi- electrode lead 107 still allows for continuous readjustments of the optimal electrode location. The electrode lead 109 is placed in the right ventricle of the heart with an active fixation helix at the end 116 which is embedded into the cardiac septum.
- Electrode lead 109 is provided with one or multiple electrodes 113,114,115. Electrode lead 109 is placed in the heart in a procedure similar to the typical placement procedures for cardiac right ventricle leads. Electrode lead 109 is placed in the heart using the standard cardiac lead devices which include introducers, guide catheters, guidewires, and/or stylets. Electrode lead 109 is inserted into the clavicle vein, through the superior vena cava, through the right atrium and down into the right ventricle. Electrode lead 109 is positioned under fluoroscopy into the location the clinician has determined is clinically optimal and logistically practical for fixating the electrode lead 109.
- the active fixation helix 116 is advanced and screwed into the cardiac tissue to secure electrode lead 109 onto the septum.
- the electrode lead 108 is placed in the right atrium using an active fixation helix 118.
- the distal tip electrode 118 is used to both provide pacing and motion sensing of the right atrium.
- FIG. 8 shows the configuration of electrodes around a hermetically sealed integrated circuit according to an embodiment of the invention.
- One of four electrodes 1 is distributed around the hermetically sealed IC 2 in a circumferential pattern.
- Electrode 1 is shown as a solid surface but it may have a finer scale pattern formed into the surface that improves the flexibility of the electrode.
- IC chip 2 is hermetically sealed and provides a multiplexed connection to conductors in the lead (not shown in this figure).
- top cap 3 is bonded to the integrated circuit. Cap 3 is a component that helps support the electrode to integrated circuit connection.
- Cap 3 may contain additional circuits or sensors. This assembly would be incorporated into a flexible polymeric material to form the body of the device.
- the device may be round. It may also be some other shape best suited to the particular location in the body where is would be used.
- Additional electrode structures in which the subject hermetically sealed integrated circuits find use include, but are not limited to: United States Provisional Patent Application Serial No. 60/638,692 filed December 22, 2004; United States Provisional Patent Application Serial No. 60/655,609 filed February 22, 2005; United States Provisional Patent Application Serial No. 60/655,609 filed February 22, 2005; United States Provisional Patent Application Serial No.
- analyte detection devices such as blood analyte detection devices, e.g., blood glucose detection devices.
- blood analyte detection devices e.g., blood glucose detection devices.
- analyte detection devices include a light source, e.g., an infrared or near infra-red light source, for illuminating a fluid sample, e.g., blood, and a detector for detecting return light, e.g., reflected, refracted, etc., from the sample, where signals generated by the detector in response to light from the sample are processed (e.g., by comparing to a reference or control) to detect, either qualitatively or quantitatively, one or more analytes in the sample, e.g., glucose in a blood sample.
- a light source e.g., an infrared or near infra-red light source
- return light e.g., reflected, refracted, etc.
- Infrared or near-infrared blood analyte detection devices which may be adapted to include the hermetically sealed structures, e.g., containing an infrared light source and/or detector, include, but are not limited to, those described in U.S. Published Application Nos.
- an implantable optical-based blood glucose analyte detection device in certain embodiments of the invention in which the light source, e.g., infrared light source, is hermetically sealed in a silicon holder which is transparent to infrared light.
- the hermetically sealed light source is placed on a first side of a suitable blood vessel, such that light from the sealed light source can illuminate blood in the vessel.
- a hermetically sealed detector On the opposing side of the blood vessel is placed a hermetically sealed detector, which detector detects light from blood present in the vessel and generates electrical signal in response thereto.
- the hermetically sealed light source and detector are each coupled to a control unit, e.g., via at least one conductor, which provides actuation signals to the light source and receives signals from the detector, e.g., for subsequent processing, for example to qualitatively or quantitatively determine analyte, e.g., glucose, in blood in the vessel.
- a control unit e.g., via at least one conductor, which provides actuation signals to the light source and receives signals from the detector, e.g., for subsequent processing, for example to qualitatively or quantitatively determine analyte, e.g., glucose, in blood in the vessel.
- analyte e.g., glucose
- vision restoration devices and systems e.g., devices and systems that include implantable photodetector elements that convert detected light to electrical signals, e.g., for stimulating the optic nerve.
- integrated circuits and photosensors e.g., photovoltaic cells
- Representative implantable vision restoration devices and systems in which the subject hermetically sealed structures may be incorporated include, but are not limited to those devices and systems described in: U.S. Patent Nos.
- kits that include the subject hermetically sealed structures, as part of one or more components of an implantable device or system, such as the devices and systems reviewed above.
- the kits further include at least a control unit, e.g., in the form of a pacemaker can.
- the structure and control unit may be electrically coupled by an elongated conductive member.
- the hermetically sealed structure may be present in a lead, such as a cardiovascular lead.
- kits will further include instructions for using the subject devices or elements for obtaining the same (e.g., a website URL directing the user to a webpage which provides the instructions), where these instructions are typically printed on a substrate, which substrate may be one or more of: a package insert, the packaging, reagent containers and the like.
- a substrate may be one or more of: a package insert, the packaging, reagent containers and the like.
- the one or more components are present in the same or different containers, as may be convenient or desirable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Prostheses (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63869204P | 2004-12-22 | 2004-12-22 | |
US65560905P | 2005-02-22 | 2005-02-22 | |
US68191905P | 2005-05-16 | 2005-05-16 | |
US69778905P | 2005-07-08 | 2005-07-08 | |
PCT/US2005/046815 WO2006069323A1 (en) | 2004-12-22 | 2005-12-22 | Implantable hermetically sealed structures |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1827583A1 true EP1827583A1 (en) | 2007-09-05 |
EP1827583A4 EP1827583A4 (en) | 2010-04-21 |
EP1827583B1 EP1827583B1 (en) | 2013-01-23 |
Family
ID=36602098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05855386A Not-in-force EP1827583B1 (en) | 2004-12-22 | 2005-12-22 | Implantable hermetically sealed structures |
Country Status (4)
Country | Link |
---|---|
US (1) | US8195308B2 (en) |
EP (1) | EP1827583B1 (en) |
JP (2) | JP5254622B2 (en) |
WO (1) | WO2006069323A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113506748A (en) * | 2021-09-08 | 2021-10-15 | 南通汇丰电子科技有限公司 | Semiconductor stacking component and preparation method thereof |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006509547A (en) | 2002-12-11 | 2006-03-23 | プロテウス バイオメディカル インコーポレイテッド | Method and system for monitoring and treating hemodynamic parameters |
WO2006052763A2 (en) | 2004-11-04 | 2006-05-18 | Microchips, Inc. | Compression and cold weld sealing methods and devices |
WO2007021804A2 (en) | 2005-08-12 | 2007-02-22 | Proteus Biomedical, Inc. | Evaluation of depolarization wave conduction velocity |
WO2007120290A2 (en) | 2005-11-22 | 2007-10-25 | Proteus Biomedical, Inc. | External continuous field tomography |
JP5241714B2 (en) | 2006-07-07 | 2013-07-17 | プロテウス デジタル ヘルス, インコーポレイテッド | Smart parenteral delivery system |
US8019416B2 (en) | 2006-11-13 | 2011-09-13 | Cardiac Pacemakers, Inc. | Reduction of AV delay for treatment of cardiac disease |
US8055345B2 (en) | 2007-08-31 | 2011-11-08 | Proteus Biomedical, Inc. | Self-referencing communication in implantable devices |
US8972007B2 (en) | 2007-09-25 | 2015-03-03 | Cardiac Pacemakers, Inc. | Variable shortening of AV delay for treatment of cardiac disease |
JP2010540073A (en) | 2007-09-27 | 2010-12-24 | カーディアック ペースメイカーズ, インコーポレイテッド | Embedded lead wire with electrical stimulation capacitor |
US9125979B2 (en) | 2007-10-25 | 2015-09-08 | Proteus Digital Health, Inc. | Fluid transfer port information system |
WO2009067463A1 (en) | 2007-11-19 | 2009-05-28 | Proteus Biomedical, Inc. | Body-associated fluid transport structure evaluation devices |
EP2087838A1 (en) * | 2008-02-05 | 2009-08-12 | Ikerlan, S. Coop. | Metallization process to obtain a microelectrode on a photopatternable substrate and its biomedical application on an organ transplant monitoring device |
US8473069B2 (en) | 2008-02-28 | 2013-06-25 | Proteus Digital Health, Inc. | Integrated circuit implementation and fault control system, device, and method |
US20090248107A1 (en) | 2008-03-25 | 2009-10-01 | Medtronic, Inc. | Robust High Power and Low Power Cardiac Leads Having Integrated Sensors |
US8849424B2 (en) | 2008-03-25 | 2014-09-30 | Medtronic, Inc. | Integrated conductive sensor package having conductor bypass, distal electrode, distal adapter and custom molded overlay |
US8788042B2 (en) | 2008-07-30 | 2014-07-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Apparatus and method for optimized stimulation of a neurological target |
US8389862B2 (en) | 2008-10-07 | 2013-03-05 | Mc10, Inc. | Extremely stretchable electronics |
US8886334B2 (en) | 2008-10-07 | 2014-11-11 | Mc10, Inc. | Systems, methods, and devices using stretchable or flexible electronics for medical applications |
JP5646492B2 (en) | 2008-10-07 | 2014-12-24 | エムシー10 インコーポレイテッドMc10,Inc. | Stretchable integrated circuit and device with sensor array |
JP5667987B2 (en) | 2008-11-12 | 2015-02-12 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) | Micromachined nerve stimulation device |
KR101088806B1 (en) * | 2009-01-07 | 2011-12-01 | 주식회사 뉴로바이오시스 | Microelectrode array package using liquid crystal polymer and manufacturing method thereof |
US8343806B2 (en) | 2009-03-05 | 2013-01-01 | Raytheon Company | Hermetic packaging of integrated circuit components |
EP2424588A4 (en) | 2009-04-29 | 2013-05-22 | Proteus Digital Health Inc | Methods and apparatus for leads for implantable devices |
US20100314149A1 (en) | 2009-06-10 | 2010-12-16 | Medtronic, Inc. | Hermetically-sealed electrical circuit apparatus |
US8172760B2 (en) | 2009-06-18 | 2012-05-08 | Medtronic, Inc. | Medical device encapsulated within bonded dies |
EP2457241A2 (en) | 2009-07-23 | 2012-05-30 | Proteus Biomedical, Inc. | Solid-state thin film capacitor |
US20110077699A1 (en) * | 2009-09-30 | 2011-03-31 | John Swanson | Medical leads with segmented electrodes and methods of fabrication thereof |
US9723122B2 (en) | 2009-10-01 | 2017-08-01 | Mc10, Inc. | Protective cases with integrated electronics |
CA3026948C (en) | 2009-12-01 | 2022-07-12 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device and methods of making and using the same |
WO2011072286A1 (en) * | 2009-12-11 | 2011-06-16 | Keith Leonard March | Implantable biomedical device leads comprising liquid conductors |
FR2955260A1 (en) * | 2010-01-15 | 2011-07-22 | Commissariat Energie Atomique | Medical probe e.g. deep electric neurostimulation probe, for acquiring or delivering signals inside patient's body, has planar substrate placed inside of probe body and provided with orientation perpendicular to longitudinal axis of probe |
AU2011210648B2 (en) | 2010-02-01 | 2014-10-16 | Otsuka Pharmaceutical Co., Ltd. | Data gathering system |
KR20120114368A (en) | 2010-02-01 | 2012-10-16 | 프로테우스 디지털 헬스, 인코포레이티드 | Two-wrist data gathering system |
US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
TWI423381B (en) | 2010-04-27 | 2014-01-11 | Inotera Memories Inc | Auxiliary stage and method of utilizing auxiliary stage |
US8546903B2 (en) * | 2010-10-07 | 2013-10-01 | Texas Instruments Incorporated | Ionic isolation ring |
US8718770B2 (en) | 2010-10-21 | 2014-05-06 | Medtronic, Inc. | Capture threshold measurement for selection of pacing vector |
US8688223B2 (en) | 2010-10-26 | 2014-04-01 | John D. Wahlstrand | Implantable medical device impedance measurement module for communication with one or more lead-borne devices |
US8666505B2 (en) | 2010-10-26 | 2014-03-04 | Medtronic, Inc. | Wafer-scale package including power source |
US8509899B2 (en) | 2010-12-23 | 2013-08-13 | Medtronic, Inc. | Multi-electrode implantable systems and assemblies thereof |
US8424388B2 (en) | 2011-01-28 | 2013-04-23 | Medtronic, Inc. | Implantable capacitive pressure sensor apparatus and methods regarding same |
KR101144532B1 (en) * | 2011-02-17 | 2012-05-11 | 주식회사 뉴로바이오시스 | Micro-electrode Array Package using Liquid Crystal Polymer |
US8355784B2 (en) | 2011-05-13 | 2013-01-15 | Medtronic, Inc. | Dynamic representation of multipolar leads in a programmer interface |
US9159635B2 (en) | 2011-05-27 | 2015-10-13 | Mc10, Inc. | Flexible electronic structure |
US9171794B2 (en) | 2012-10-09 | 2015-10-27 | Mc10, Inc. | Embedding thin chips in polymer |
US10464836B2 (en) | 2013-10-10 | 2019-11-05 | Medtronic, Inc. | Hermetic conductive feedthroughs for a semiconductor wafer |
KR20160147912A (en) * | 2014-04-25 | 2016-12-23 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | Method and ophthalmic device with active agent release system |
US10966620B2 (en) | 2014-05-16 | 2021-04-06 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US10835126B1 (en) | 2015-11-06 | 2020-11-17 | Verily Life Sciences Llc | Implantable micro-spectrophotometer |
CN109069824B (en) | 2016-02-02 | 2022-09-16 | 阿莱瓦神经治疗股份有限公司 | Treatment of autoimmune diseases using deep brain stimulation |
WO2018005373A1 (en) | 2016-06-27 | 2018-01-04 | Cardiac Pacemakers, Inc. | Cardiac therapy system using subcutaneously sensed p-waves for resynchronization pacing management |
US10426962B2 (en) | 2016-07-07 | 2019-10-01 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
WO2018039335A1 (en) | 2016-08-24 | 2018-03-01 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using p-wave to pace timing |
CN109641129B (en) | 2016-08-24 | 2023-06-30 | 心脏起搏器股份公司 | Cardiac resynchronization with timing management using fusion facilitation |
US10765871B2 (en) | 2016-10-27 | 2020-09-08 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
WO2018081275A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
DE102016222710A1 (en) * | 2016-11-18 | 2018-05-24 | Neuroloop GmbH | Implantable electrical contact arrangement |
US10894163B2 (en) | 2016-11-21 | 2021-01-19 | Cardiac Pacemakers, Inc. | LCP based predictive timing for cardiac resynchronization |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
US11253710B2 (en) * | 2017-01-05 | 2022-02-22 | Cardiac Pacemakers, Inc. | Chip or silicon based feedthrough |
WO2018140623A1 (en) | 2017-01-26 | 2018-08-02 | Cardiac Pacemakers, Inc. | Leadless device with overmolded components |
WO2019036600A1 (en) | 2017-08-18 | 2019-02-21 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
KR102610591B1 (en) * | 2018-09-11 | 2023-12-07 | 삼성전자주식회사 | Apparatus and method for health care |
EP3806496A1 (en) * | 2019-10-08 | 2021-04-14 | Oticon A/s | A hearing device comprising a detector and a trained neural network |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943936A (en) * | 1970-09-21 | 1976-03-16 | Rasor Associates, Inc. | Self powered pacers and stimulators |
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
EP0314937A2 (en) * | 1987-10-08 | 1989-05-10 | Pacesetter AB | Implantable blood oxygen sensor and method of use |
EP0518364A2 (en) * | 1991-06-14 | 1992-12-16 | Pacesetter, Inc. | Pacemaker lead for sensing a physiologic parameter of the body |
US5314458A (en) * | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
WO1997037720A1 (en) * | 1996-04-04 | 1997-10-16 | Medtronic, Inc. | Living tissue stimulation and recording techniques |
US20020165589A1 (en) * | 2001-05-01 | 2002-11-07 | Imran Mir A. | Gastric treatment and diagnosis device and method |
WO2002089655A2 (en) * | 2001-05-01 | 2002-11-14 | Intrapace, Inc. | Submucosal gastric implant device and method |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5524338A (en) | 1991-10-22 | 1996-06-11 | Pi Medical Corporation | Method of making implantable microelectrode |
US5551553A (en) | 1992-08-11 | 1996-09-03 | Stamet, Inc. | Angled disk drive apparatus for transporting and metering particulate material |
US5511533A (en) * | 1994-02-03 | 1996-04-30 | Waller; Charles O. | Adjustable hydraulic stabilizer for a bow |
US5697377A (en) | 1995-11-22 | 1997-12-16 | Medtronic, Inc. | Catheter mapping system and method |
US6051017A (en) * | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
FR2796562B1 (en) | 1996-04-04 | 2005-06-24 | Medtronic Inc | TECHNIQUES FOR STIMULATING LIVING TISSUE AND RECORDING WITH LOCAL CONTROL OF ACTIVE SITES |
US5772108A (en) | 1996-04-24 | 1998-06-30 | Con Pac South, Inc. | Reinforced paperboard container |
US5963429A (en) | 1997-08-20 | 1999-10-05 | Sulzer Intermedics Inc. | Printed circuit substrate with cavities for encapsulating integrated circuits |
US5999848A (en) | 1997-09-12 | 1999-12-07 | Alfred E. Mann Foundation | Daisy chainable sensors and stimulators for implantation in living tissue |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
US6266567B1 (en) | 1999-06-01 | 2001-07-24 | Ball Semiconductor, Inc. | Implantable epicardial electrode |
US6631555B1 (en) | 2000-02-08 | 2003-10-14 | Cardiac Pacemakers, Inc. | Method of thin film deposition as an active conductor |
US7096070B1 (en) | 2000-02-09 | 2006-08-22 | Transneuronix, Inc. | Medical implant device for electrostimulation using discrete micro-electrodes |
US7481759B2 (en) * | 2001-08-03 | 2009-01-27 | Cardiac Pacemakers, Inc. | Systems and methods for treatment of coronary artery disease |
US7142909B2 (en) | 2002-04-11 | 2006-11-28 | Second Sight Medical Products, Inc. | Biocompatible bonding method and electronics package suitable for implantation |
JP2003347460A (en) * | 2002-05-28 | 2003-12-05 | Kyocera Corp | Electronic equipment |
US7162289B2 (en) * | 2002-09-27 | 2007-01-09 | Medtronic Minimed, Inc. | Method and apparatus for enhancing the integrity of an implantable sensor device |
JP2006509547A (en) * | 2002-12-11 | 2006-03-23 | プロテウス バイオメディカル インコーポレイテッド | Method and system for monitoring and treating hemodynamic parameters |
US20050038481A1 (en) | 2003-08-11 | 2005-02-17 | Edward Chinchoy | Evaluating ventricular synchrony based on phase angle between sensor signals |
US7214189B2 (en) | 2004-09-02 | 2007-05-08 | Proteus Biomedical, Inc. | Methods and apparatus for tissue activation and monitoring |
JP2008515548A (en) | 2004-10-08 | 2008-05-15 | プロテウス バイオメディカル インコーポレイテッド | Continuous field tomography |
US7673679B2 (en) | 2005-09-19 | 2010-03-09 | Schlumberger Technology Corporation | Protective barriers for small devices |
-
2005
- 2005-12-22 JP JP2007548534A patent/JP5254622B2/en not_active Expired - Fee Related
- 2005-12-22 WO PCT/US2005/046815 patent/WO2006069323A1/en active Application Filing
- 2005-12-22 EP EP05855386A patent/EP1827583B1/en not_active Not-in-force
- 2005-12-22 US US11/794,016 patent/US8195308B2/en active Active
-
2011
- 2011-10-28 JP JP2011237739A patent/JP2012050849A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943936A (en) * | 1970-09-21 | 1976-03-16 | Rasor Associates, Inc. | Self powered pacers and stimulators |
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
EP0314937A2 (en) * | 1987-10-08 | 1989-05-10 | Pacesetter AB | Implantable blood oxygen sensor and method of use |
US5314458A (en) * | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
EP0518364A2 (en) * | 1991-06-14 | 1992-12-16 | Pacesetter, Inc. | Pacemaker lead for sensing a physiologic parameter of the body |
WO1997037720A1 (en) * | 1996-04-04 | 1997-10-16 | Medtronic, Inc. | Living tissue stimulation and recording techniques |
US20020165589A1 (en) * | 2001-05-01 | 2002-11-07 | Imran Mir A. | Gastric treatment and diagnosis device and method |
WO2002089655A2 (en) * | 2001-05-01 | 2002-11-14 | Intrapace, Inc. | Submucosal gastric implant device and method |
Non-Patent Citations (1)
Title |
---|
See also references of WO2006069323A1 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113506748A (en) * | 2021-09-08 | 2021-10-15 | 南通汇丰电子科技有限公司 | Semiconductor stacking component and preparation method thereof |
CN113506748B (en) * | 2021-09-08 | 2021-11-12 | 南通汇丰电子科技有限公司 | Semiconductor stacking component and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5254622B2 (en) | 2013-08-07 |
JP2008525121A (en) | 2008-07-17 |
US8195308B2 (en) | 2012-06-05 |
JP2012050849A (en) | 2012-03-15 |
EP1827583A4 (en) | 2010-04-21 |
US20080312726A1 (en) | 2008-12-18 |
WO2006069323A1 (en) | 2006-06-29 |
EP1827583B1 (en) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8195308B2 (en) | Implantable hermetically sealed structures | |
JP5539448B2 (en) | Embedded sealed structure without voids | |
EP2416841B1 (en) | Electronics package for an active implantable medical device | |
US9431312B2 (en) | Wafer-scale package including power source | |
EP1833551B1 (en) | Implantable addressable segmented electrodes | |
US20100131023A1 (en) | Implantable medical devices comprising cathodic arc produced structures | |
US9126825B2 (en) | Implantable biocompatible component integrating an active sensor for measurement of a physiological parameter, a micro-electromechanical system or an integrated circuit | |
US20080114230A1 (en) | Electrode support | |
US20080154365A1 (en) | Method for integrating pre-fabricated chip structures into functional electronic systems | |
AU2009344197A1 (en) | Bonded hermetic feed through for an active implantable medical device | |
WO2007127622A2 (en) | Contactless interconnect for transducers | |
WO2008134615A2 (en) | Metallization with tailorable coefficient of thermal expansion | |
KR20220113405A (en) | Implantable Stimulator with Electrode Array and Compliant Substrate | |
EP2660190B1 (en) | Encapsulated component with active element and implantable medical device comprising said component | |
EP2142083A2 (en) | Layered structure for corrosion resistant interconnect contacts | |
US8172760B2 (en) | Medical device encapsulated within bonded dies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070703 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: JENSEN, MARC Inventor name: FRANK, JEREMY Inventor name: GELFANDBEIN, VLADIMIR Inventor name: COSTELLO, BENEDICT, J. Inventor name: ZDEBLICK, MARK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100323 |
|
17Q | First examination report despatched |
Effective date: 20100715 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61N 1/375 20060101ALI20120717BHEP Ipc: A61N 1/05 20060101AFI20120717BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GELFANDBEIN, VLADIMIR Inventor name: ZDEBLICK, MARK Inventor name: COSTELLO, BENEDICT, J. Inventor name: FRANK, JEREMY Inventor name: JENSEN, MARC |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROTEUS DIGITAL HEALTH, INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: JENSEN, MARC Inventor name: COSTELLO, BENEDICT, J. Inventor name: THE OTHER INVENTORS HAVE AGREED TO WAIVE THEIR ENT Inventor name: GELFANDBEIN, VLADIMIR |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 594627 Country of ref document: AT Kind code of ref document: T Effective date: 20130215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005038027 Country of ref document: DE Effective date: 20130321 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 594627 Country of ref document: AT Kind code of ref document: T Effective date: 20130123 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130423 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130523 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130504 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130523 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
26N | No opposition filed |
Effective date: 20131024 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005038027 Country of ref document: DE Effective date: 20131024 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131222 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131222 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20051222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130123 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602005038027 Country of ref document: DE Representative=s name: MURGITROYD GERMANY PATENTANWALTSGESELLSCHAFT M, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602005038027 Country of ref document: DE Representative=s name: MURGITROYD & COMPANY, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602005038027 Country of ref document: DE Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP Free format text: FORMER OWNER: PROTEUS DIGITAL HEALTH, INC., REDWOOD CITY, CALIF., US |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20210415 AND 20210421 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20211224 Year of fee payment: 17 Ref country code: DE Payment date: 20211220 Year of fee payment: 17 Ref country code: GB Payment date: 20211220 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602005038027 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20221222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221223 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221222 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230701 |